Limits...
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

Lotem M, Peretz T, Drize O, Gimmon Z, Ad El D, Weitzen R, Goldberg H, Ben David I, Prus D, Hamburger T, Shiloni E - Br. J. Cancer (2002)

Bottom Line: In contrast, patients with a negative or weak delayed type hypersensitivity had a median disease free survival of 9 months (relative risk of recurrence=4.5, P=0.001), and a median overall survival of 16 months (relative risk of death=15, P=0.001).Stage III patients with a positive delayed type hypersensitivity reaction had an improved disease free survival of 16 months and a mean overall survival of 38 months, whereas patients with a negative delayed type hypersensitivity had a median disease free survival of 7 months (relative risk=4.5, P=0.02) and a median overall survival of 16 months (relative risk=9.5, P=0.005).The adjuvant administration of autologous melanoma vaccine was associated with improved disease-free and overall survival to selected patients who successfully attained anti-melanoma reactivity as detected by positive delayed type hypersensitivity reactions to unmodified melanoma cells.

View Article: PubMed Central - PubMed

Affiliation: Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel 91120. lotem@isdn.net.il

Show MeSH

Related in: MedlinePlus

Kaplan-Meier estimates of (A) overall survival and (B) disease free survival as a function of DTH status for all patients.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2746603&req=5

fig2: Kaplan-Meier estimates of (A) overall survival and (B) disease free survival as a function of DTH status for all patients.

Mentions: Current patient status with respect to DTH response. The number of patients in each of three categories. NED: no evidence of disease; AWD: alive with disease; Exitus: deceased. In each of these categories, the patients were divided into two groups according to the pattern of the delayed type hyper-sensitivity (DTH).


Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

Lotem M, Peretz T, Drize O, Gimmon Z, Ad El D, Weitzen R, Goldberg H, Ben David I, Prus D, Hamburger T, Shiloni E - Br. J. Cancer (2002)

Kaplan-Meier estimates of (A) overall survival and (B) disease free survival as a function of DTH status for all patients.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2746603&req=5

fig2: Kaplan-Meier estimates of (A) overall survival and (B) disease free survival as a function of DTH status for all patients.
Mentions: Current patient status with respect to DTH response. The number of patients in each of three categories. NED: no evidence of disease; AWD: alive with disease; Exitus: deceased. In each of these categories, the patients were divided into two groups according to the pattern of the delayed type hyper-sensitivity (DTH).

Bottom Line: In contrast, patients with a negative or weak delayed type hypersensitivity had a median disease free survival of 9 months (relative risk of recurrence=4.5, P=0.001), and a median overall survival of 16 months (relative risk of death=15, P=0.001).Stage III patients with a positive delayed type hypersensitivity reaction had an improved disease free survival of 16 months and a mean overall survival of 38 months, whereas patients with a negative delayed type hypersensitivity had a median disease free survival of 7 months (relative risk=4.5, P=0.02) and a median overall survival of 16 months (relative risk=9.5, P=0.005).The adjuvant administration of autologous melanoma vaccine was associated with improved disease-free and overall survival to selected patients who successfully attained anti-melanoma reactivity as detected by positive delayed type hypersensitivity reactions to unmodified melanoma cells.

View Article: PubMed Central - PubMed

Affiliation: Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel 91120. lotem@isdn.net.il

Show MeSH
Related in: MedlinePlus